8-K/A: Nuvve Secures $5.4M Private Placement, $25M Equity Line

Nuvve Holding Corp. amended its SEC filing to detail a $5.4 million private placement of convertible preferred stock and warrants, alongside an up to $25 million equity line of credit, with significant dilution potential for existing shareholders.

Summary

• Nuvve Holding Corp. entered into a Securities Purchase Agreement on November 14, 2025, for a private placement (the "Offering").
• The Offering involves the issuance and sale of 6,000 shares of newly-designated Series A Convertible Preferred Stock (Preferred Stock) with an aggregate stated value of $6,000,000, for an aggregate purchase price of $5,400,000.
• Purchasers also received warrants (Warrants) to buy Common Stock, equal to 100% of shares convertible from the Preferred Stock, with an initial exercise price of 135% of the Common Stock's closing price prior to the Closing and a five-year term.
• The Preferred Stock is convertible at 90% of the Common Stock's closing price prior to the Closing and carries cumulative dividends of 8% per annum, potentially rising to 18% upon certain triggering events, payable quarterly in cash, shares, or a combination.
• Both the Preferred Stock and Warrants include full ratchet price protection and a floor price equal to 20% of the initial Conversion Price.
• Purchasers have an Additional Investment Right to purchase up to an additional $25,000,000 of Preferred Stock and accompanying warrants (AIR Warrants).
• The AIR Price for these additional investments is the greater of (A) the lesser of (i) 90% of the arithmetic average of the five lowest intraday trading prices over the ten trading days prior to exercise and (ii) the current conversion/exercise price, and (B) the Floor Price.
• Purchasers are obligated to exercise Additional Investment Rights or Warrants for at least $4,000,000 every six months, up to a total of $20,000,000 in gross proceeds, provided the AIR Price meets the Floor Price.
• Shareholder approval is required by December 31, 2025, for the issuance of Common Stock exceeding 19.99% of outstanding shares related to the Preferred Stock and Warrants.
• The Company also entered into an Amended and Restated Common Shares Purchase Agreement (ELOC Agreement) on December 1, 2025, with Five Narrow Lane, L.P. and Hailstone Peak Funding LLC, establishing an equity line of credit (Facility) for up to $25,000,000 of Common Stock.
• As a commitment fee for the ELOC Agreement, the Company issued pre-funded warrants to purchase an aggregate of 2,221,235 shares of Common Stock to the Investors.
• Under the ELOC, the Company can sell Common Stock at a VWAP Purchase Price equal to 93% of the lesser of the lowest sale price on the VWAP purchase date and the VWAP over the applicable purchase period.
• The Company will use the net proceeds from both the private placement and the ELOC for working capital and general purposes.
• The Company will use its reasonable best efforts to convert existing outstanding indebtedness into Common Stock on or before December 31, 2025.

Sentiment

Score: 3

Explanation: While the company secures much-needed capital, the highly dilutive terms of the convertible preferred stock (90% conversion, full ratchet, high dividends) and the discounted equity line of credit suggest a company raising funds under duress. These terms heavily favor new investors at the significant expense of existing common shareholders, indicating potential financial strain or a very high-risk profile.

Positives

• Secured immediate capital of $5.4 million through the private placement, providing crucial liquidity.
• Established an equity line of credit for up to an additional $25 million, offering flexible access to future capital.
• Purchasers are obligated to make further investments/warrant exercises totaling at least $20 million over time, ensuring a committed funding source.
• The financing includes registration rights for the resale of securities, which facilitates liquidity for the investors.

Negatives

• The terms of the convertible preferred stock, including conversion at 90% of the closing price and full ratchet price protection, are highly dilutive to existing common shareholders.
• The high cumulative dividend rate on the preferred stock (8% per annum, potentially 18%) could place a significant strain on the company's cash flow.
• The equity line of credit allows the company to sell common stock at a 7% discount to the lesser of the lowest sale price or VWAP, guaranteeing further dilution for common shareholders.
• The company explicitly acknowledges that the issuance of securities may result in substantial dilution of outstanding common stock.
• Restrictions are placed on the company's ability to undertake certain future equity sales (Variable Rate Transactions) and stock splits without investor consent, limiting financial flexibility.
• The company is liable for liquidated damages if it fails to meet deadlines for filing and effectiveness of registration statements, or if it fails to maintain public information requirements.

Risks

• Significant dilution of outstanding Common Stock for existing shareholders due to the convertible preferred stock, warrants, and equity line of credit.
• Failure to obtain required shareholder approval by December 31, 2025, for the issuance of shares exceeding 19.99% of outstanding Common Stock.
• Potential for a Material Adverse Effect on the company's financial condition, operations, or business prospects.
• Risk of trading in the Common Stock being suspended by regulatory bodies or the principal trading market.
• Non-compliance with SEC reporting requirements, including current public information under Rule 144(c), leading to liquidated damages.
• Litigation risk, including potential stockholder actions or claims of securities law violations.
• Cybersecurity breaches or data privacy law violations impacting IT Systems and Data.
• Failure to comply with environmental laws, regulatory permits, or occupational health and safety regulations.
• Inability to renew existing insurance coverage or obtain similar coverage without significant cost increases.
• Labor disputes that could result in a Material Adverse Effect.
• Solvency issues or potential bankruptcy proceedings if the company cannot meet its debts as they mature.
• Failure to convert existing indebtedness into Common Stock by December 31, 2025, as per the agreement.

Future Outlook

The company intends to use the net proceeds from these financing activities for working capital and general corporate purposes. It plans to seek shareholder approval by December 31, 2025, for the issuance of shares exceeding certain thresholds and will use its best efforts to convert existing indebtedness into common stock by the same date. The company is committed to filing and maintaining effective registration statements for the resale of the newly issued securities.

Management Comments

• "The Company acknowledges that the issuance of the Securities may result in dilution of the outstanding shares of Common Stock, which dilution may be substantial under certain market conditions."
• "The Company further acknowledges that its obligations under the Transaction Documents, including, without limitation, its obligation to issue the Underlying Shares pursuant to the Transaction Documents, are unconditional and absolute and not subject to any right of set off, counterclaim, delay or reduction, regardless of the effect of any such dilution or any claim the Company may have against any Purchaser and regardless of the dilutive effect that such issuance may have on the ownership of the other stockholders of the Company."

Industry Context

This financing structure, involving convertible preferred stock with strong anti-dilution features, warrants, and an equity line of credit, is often utilized by companies in capital-intensive or high-growth sectors, or those facing significant financial challenges. The terms suggest a need for substantial capital infusion, potentially under conditions where traditional equity financing is less accessible or more expensive, indicating a high-risk profile or aggressive growth strategy within the company's industry (e.g., EV charging/V2G technology).

Comparison to Industry Standards

• The use of convertible preferred stock with full ratchet anti-dilution protection and a high dividend rate (8-18%) is a strong investor protection mechanism, typically seen in situations where investors demand significant upside and downside protection, often in companies with higher perceived risk or in distressed situations, which is more aggressive than standard equity raises.
• An equity line of credit (ELOC) at a 7% discount to market prices (93% of the lesser of lowest sale price or VWAP) is a common, albeit dilutive, financing tool for companies seeking flexible access to capital, but the specific discount and pricing mechanism can be more aggressive than typical at-the-market (ATM) offerings.
• The mandatory additional investment clause, obligating purchasers to invest further capital under certain conditions, provides a committed funding pipeline but also indicates a significant level of control and influence granted to these investors, which can be less common in standard growth equity rounds.

Corporate Governance

Related Party Transactions

• Five Narrow Lane, L.P. is identified as a Lead Purchaser in the Securities Purchase Agreement and an Investor in the Amended and Restated Common Shares Purchase Agreement (ELOC Agreement).
• Hailstone Peak Funding LLC is identified as an Investor in the Amended and Restated Common Shares Purchase Agreement (ELOC Agreement).

Stakeholder Impact

• **Shareholders:** Face significant potential for dilution from the conversion of preferred stock, exercise of warrants (both with full ratchet anti-dilution), and sales under the equity line of credit. The high dividend rate on preferred stock could also divert cash flow. Shareholder approval is required for substantial issuances, offering a limited check on dilution.
• **Company:** Gains immediate capital and access to substantial future funding, which is critical for operations and strategic initiatives. However, the terms of the financing are costly and restrictive, potentially impacting future financial flexibility and common equity value.
• **Investors (Purchasers):** Benefit from highly favorable terms, including significant discounts, strong anti-dilution protection, high dividend yields, and mandatory future investment obligations, positioning them with substantial protection and potential returns.

Next Steps

• The Company must hold an annual or special meeting of stockholders on or prior to December 31, 2025, to obtain Shareholder Approval for the issuance of shares exceeding 19.99% of outstanding Common Stock.
• If Shareholder Approval is not obtained at the first meeting, the Company must call subsequent meetings every thirty days until approval is secured or purchasers no longer hold Preferred Stock or Warrants.
• The Company is required to file a registration statement for the resale of securities from the private placement within 15 days of closing and for the ELOC shares within 30 trading days, and use commercially reasonable efforts to ensure their effectiveness.
• Purchasers are obligated to exercise Additional Investment Rights or Warrants for at least $4,000,000 every six months, up to a total of $20,000,000, provided certain pricing conditions are met.
• The Company will use its reasonable best efforts to enter into agreements with existing holders of outstanding indebtedness to effect conversion into Common Stock on or before December 31, 2025.
• The Company must maintain compliance with SEC reporting requirements and public information rules to avoid liquidated damages.

Key Dates

Recommendation

The financing terms are exceptionally dilutive and unfavorable for existing common shareholders. The convertible preferred stock with full ratchet anti-dilution, high dividend rates (up to 18%), and warrants, combined with an equity line of credit at a 7% discount to market, indicate a company in a precarious financial position. These terms are designed to heavily protect new investors at the direct expense of current common equity holders, suggesting significant downside risk and potential for substantial value erosion for common stock. A seasoned investor would likely view this as a signal to exit their common stock position.

Keywords

Nuvve Holding Corp., Private Placement, Convertible Preferred Stock, Warrants, Equity Line of Credit, Capital Raise, Dilution, SEC Filing, Corporate Finance, NVVE